News
Alpha-1 Canada says Ontario no longer accepting funding applications for augmentation therapy for Alphas
Alpha-1 Canada
Alpha-1 Canada has recently learned the Ontario government will no longer accept applications for funding for augmentation
therapy (Prolastin®) for alpha-1 antitrypsin deficiency.
The Ontario government has been denying funding to newly prescribed patients for over two years as they reviewed funding
for augmentation therapy. Prolastin is the only treatment available for lung-involved patients with the rare genetic disease
called alpha-1 antitrypsin deficiency.
Ontario is Canada’s largest province.
They will, we are told, continue to accept applications from patients currently on treatment; however, they will use new, yet to be developed, criteria.
Forty-four Ontarians are currently receiving this therapy (more than half funded through private insurance). As many as ten newly diagnosed Ontarians have been denied funding by the province.
